We are almost there ...
Natco just can’t kick its high-risk, high-gain game plan
CEO Rajeev Nannapaneni’s oft-used strategy of mounting patent challenges in the US got the pharma company its latest blockbuster Revlimid. But what after sales fall off a cliff?
03 October, 2024•12 min
0
03 October, 2024•12 min
0
Subscribe to read this story
We publish over 500 original, detailed stories every year on startups, corporates, stock markets and economic current affairs.
Limited time offer $125 $99 for 1 year
SUBSCRIBE
Already have an account? Sign In
More in Business
Business
Mubadala acquires a stake in Nord Anglia Education for $600 million
The investment company joins a consortium that plans to expand the UK-based private school operator’s footprint across the Middle East.
You may also like
Health
Indian pharma exporters protesting against new regulations is not a good look
The rules require exporters of certain drugs to get an NOC from importing countries—a small but much-needed step to restoring India’s credibility in the global pharma market.
Internet
Why is Swiggy catching flak for its latest quick-delivery promise?
The food and grocery delivery company’s idea of providing prescription drugs in 10 minutes is facing resistance from traditional pharma players.
Business
KKR set to hit the jackpot with JB Chemicals and Pharma
The investment giant is rumoured to be eyeing an exit with a 5x return, having taken the drugmaker from obscurity to a billion-dollar bidding war.
